Ten advances defining sudden cardiac death

Trends in Cardiovascular Medicine

Volumn 26, Issue 1, 2016, Pages 23-33

  Mitrani, Raul D ^a   Myerburg, Robert J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHLETE; AUTOMATED EXTERNAL DEFIBRILLATOR; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; HEART PROTECTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; OUT OF HOSPITAL CARDIAC ARREST; PATIENT SELECTION; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUDDEN CARDIAC DEATH; ARRHYTHMIAS, CARDIAC; CARDIOVERSION; COMPLICATION; DEATH, SUDDEN, CARDIAC; DEVICES; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RISK ASSESSMENT;

ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HUMANS; PRIMARY PREVENTION; RISK ASSESSMENT;

EID: 84958777827     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2015.03.017     Document Type: Review

References (49)

1. Myerburg R.J., Castellanos A. Cardiac arrest and sudden cardiac death. Braunwald's heart disease: a textbook of cardiovascular medicine 2015, 821-860. Elsevier Sanders, Philadelphia, PA. 10th ed. D.L. Mann, D.P. Zipes, P. Libby, R.O. Bonow, E. Braunwald (Eds.).
2. Myerburg R.J., Junttila M.J. Sudden cardiac death caused by coronary heart disease. Circulation 2012, 125:1043-1052.
3. Myerburg R.J., Ullmann S.G. Alternative research funding to improve clinical outcomes: the model of prediction and prevention of sudden cardiac death. Circ Arrhythm Electrophysiol 2015, 8:492-498.
4. Myerburg R.J., Halperin H., Egan D.A. Pulseless electric activity. Definition, causes, mechanisms management and research pririties for the next decade: report from a NHLBI Workshop. Circulation 2013, 128:2532-2541.
5. Girotra S., Nallamothu B.K., Spertus J.A., Li Y., Krumholz H.M., Chan P.S., et al. Trends in survival after in-hospital cardiac arrest. N Engl J Med 2012, 367:1912-1920.
6. Herlitz J., Svensson L., Engdahl J., Silfverstolpe J. Characteristics and outcome in out-of-hospital cardiac arrest when patients are found in a non-shockable rhythm. Resuscitation 2008, 76:31-36.
7. Goldberger J.J., Basu A., Boineau R., et al. Risk stratification for sudden cardiac death: a plan for the future. Circulation 2014, 129:516-526.
8. Fishman G.I., Chugh S.S., Dimarco J.P., Albert C.M., Anderson M.E., Bonow R.O., et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010, 122:2335-2348.
9. Goldberger J.J., Cain M.E., Hohnloser S.H., Kadish A.H., Knight B.P., Lauer M.S., et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Heart Rhythm 2008, 5:e1-21.
10. Huikuri H.V., Stein P.K. Heart rate variability in risk stratification of cardiac patients. Prog Cardiovasc Dis 2013, 56:153-159.
11. Das M.K., Suradi H., Maskoun W., Michael M.A., Shen C., Peng J., et al. Fragmented wide QRS on a 12-lead ECG: a sign of myocardial scar and poor prognosis. Circ Arrhythm Electrophysiol 2008, 1:258-268.
12. Gulati A., Jabbour A., Ismail T.F., et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. J Am Med Assoc 2013, 309:896-908.
13. Chan R.H., Maron B.J., Olvotto I., et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014, 130:484-495.
14. Fallavollita J.A., Heavey B.M., Luisi A.J., et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014, 63:141-149.
15. Jacobson A.F., Senior R., Cerqueira M.D., Wong N.D., Thomas G.S., Lopez V.A., et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010, 55:2212-2221.
16. Priori S.G., Wilde A.A., Horie M., Cho Y., Behr E.R., Berul C., et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013, 10:1932-1963.
17. Rosso R., Glikson E., Belhassen B., Katz A., Halkin A., Steinvil A., et al. Distinguishing "benign" from "malignant early repolarization": the value of the ST-segment morphology. Heart Rhythm 2012, 9:225-229.
18. Lambiase P.D., Barr C., Theuns D.A., Knops R., Neuzil P., Johansen J.B., et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J 2014, 35:1657-1665.
19. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
20. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877-883.
21. Russo A.M., Stainback R.F., Bailey S.R., et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 Appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy. J AM Coll Cardiol 2013, 61:1323-1373.
22. CMS Medicare national coverage determination. Implantable cardioverter defibrillators. 20-4. In: Services DoHaH, CMS Manual System; 2005.
23. Kusumoto F.M., Calkins H., Boehmer J., Buxton A.E., Chung M.K., Gold M.R., et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Heart Rhythm 2014, 11:1271-1303.
24. Kini V., Soufi M.K., Deo R., Epstein A.E., Bala R., Riley M., et al. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met?. J Am Coll Cardiol 2014, 63:2388-2394.
25. Moss A.J., Schuger C., Beck C.A., Brown M.W., Cannom D.S., Daubert J.P., et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012, 367:2275-2283.
26. Mitrani R.D., Sager S.J., Moscucci M., Cogan J., Myerburg R.J. Transient variations of transthoracic impedance as a predictor of heart failure and death in patients with implanted defibrillators. Int J Cardiol 2014, 175:473-477.
27. Marijon E., Tafflet M., Celermajer D.S., Dumas F., et al. Sports-related sudden death in the general population. Circulation 2011, 124:672-681.
28. Chugh S.S., Weiss J.B. Sudden cardiac death in the older athlete. J Am Coll Cardiol 2015, 65:493-502.
29. Risgaard B., Winkel B.G., Jabbari R., Glinge C., Ingemann-Hansen O., Thomsen J.L., et al. Sports-related sudden cardiac death in a competitive and a noncompetitive athlete population aged 12 to 49 years: data from an unselected nationwide study in Denmark. Heart Rhythm 2014, 11:1673-1681.
30. Kim J.H., Malhotra R., Chiampas G., et al. Cardiac arrest during long-distance running races. N Engl J Med 2012, 366:130-140.
31. Redelmeier D.A., Greenwald J.A. Competing risks of mortality with marathons: retrospective analysis. British Med J 2007, 335:1275-1277.
32. Yankelson L., Sadeh B., Gershovitz L., Werthein J., Heller K., Halpern P., et al. Life-threatening events during endurance sports: is heat stroke more prevalent than arrhythmic death?. J Am Coll Cardiol 2014, 64:463-469.
33. Harris K.M., Henry J.T., Rohman E., Haas T.S., Maron B.J. Sudden death during the triathlon. J Am Med Assoc 2010, 303:1255-1257.
34. Maron B.J. Hypertrophic Cardiomyopathy. Braunwald's heart disease: a textbook of cardiovascular medicine 2015, 1574-1588. Elsevier, Philadelphia, PA. 10th ed. D.L. Mann, D.P. Zips, P. Libby, R.O. Bonow, E. Braunwald (Eds.).
35. Maron B.J., Maron M.S. Hypertrophic cardiomyopathy. Lancet 2013, 381:242-255.
36. Harris K.M., Spirito P., Maron M.S., et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006, 114:215-225.
37. Ackerman M.J., Priori S.G., Willems S., Berul C., Brugada R., Calkins H., et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011, 8:1308-1339.
38. Hu D., Barajas-Martínez H., Pfeiffer R., Dezi F., Pfeiffer J., Buch T. Mutations in SCN10A responsible for a large fraction of Brugada syndrome cases. J AM Coll Cardiol 2014, 64:66-79.
39. Field J.M., Hazinski M.F., Sayre M.R., Chameides L., Schexnayder S.M., Hemphill R., et al. 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science. Circulation 2010, 122:S639-S933.
40. Chung M.K., Szymkiewicz S.J., Shao M., et al. Aggregate national experience with the wearable cardioverter-defibrillator. event rates compliance and survival. J AM Coll Cardiol 2010, 56:194-203.
41. Mitrani R.D., McArdle A., Slane M., Cogan J., Myerburg R.J. Wearable defibrillators in uninsured patients with newly diagnosed cardiomyopathy or recent revascularization in a community medical center. American Heart J 2013, 165:386-392.
42. Weisfeldt M.L., Becker L.B. Resuscitation after cardiac arrest: a 3-phase time-sensitive model. J Am Med Assoc 2002, 288:3035-3038.
43. Ewy G.A., Sanders A.B. Alternative approach to improving survival of patients with out-of-hospital primary cardiac arrest. J Am Coll Cardiol 2013, 61:113-118.
44. Sakamoto T., Morimura N., Hagao K., Asai Y., Yolota H., Nara S., et al. SAVE-J Study Group. Extracorporeal CPR vs conventional CPR in adults with out-of-hospital cardiac arrest: a prospective observational study. Resuscitation 2014, 85:762-768.
45. Hagihara A., Hasegawa M., Abe T., Nagata T., Wakata Y., Miyazaki S. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. J Am Med Assoc 2012, 307:1161-1168.
46. Dumas F., Bougouin W., Geri G., Lamhaut L., Bougle A., Daviaud F., et al. Is epinephrine during cardiac arrest associated with worse outcomes in resuscitated patients?. J Am Coll Cardiol 2014, 64:2360-2367.
47. Nolan J.P. Advances in post-resuscitation care. Clin Med 2011, 11:605-608.
48. Group HACAS Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002, 346:8.
49. Nielsen N., Wetterslev J., Cronberg T., Erlinge D., Gasche Y., Hassager C., et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med 2013, 369:2197-2206.